MA-EXCEL-DRYER
30.6.2020 22:17:10 CEST | Business Wire | Press release
The topic of hygiene has come to the forefront in mainstream media as reopening plans are introduced around the globe. While leading health organizations like the World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC), recommend the use of hand dryers, misinformation about them remains online, and continues to be quoted and perpetuated. Leaders from Excel Dryer , manufacturer of XLERATOR® Hand Dryers, wish to deliver a message to educate the professionals, consultants and government officials who are creating reopening guidelines, and the general public, especially in times of COVID-19: Excel hand dryers are a safe, hygienic touchless solution and an effective way to achieve completely dry hands, a critical part of proper hand hygiene , the top defense against the spread of germs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630006010/en/
Kelly Reynolds, Ph.D., Professor and Department Chair at the Mel & Enid Zuckerman College of Public Health at the University of Arizona, offered an explanation as to the root of these misconceptions, stating that, “Consumers may only read [sensationalized] headlines which can influence public opinion toward biased or erroneous conclusions, [but] the fact is, the breadth of data available does not favor one hand drying method as being more hygienic or safer.”
Excel hand dryers provide a touchless hand drying solution to help prevent potential cross-contamination between restroom surfaces and wet hands. All dryers in Excel’s line are hygienic, but dryers with HEPA have been proven to add another level of protection. Viral efficiency testing conducted by the preeminent independent air media and filter testing company, LMS Technologies in April of 2020 found that XLERATOR® , XLERATOReco ® and XLERATORsync® Hand Dryers with HEPA Filtration Systems remove 99.999 percent of viruses from the airstream.
William Gagnon, vice president of marketing and sales at Excel Dryer, wishes to correct misinformation and biases about hand dryers. “Hand dryers are hygienic and have been used to properly dry hands for decades. In addition to top health organizations recommending their use, hand dryers also provide significant benefits over paper that are undisputable. For example, our recent test results prove XLERATOR hand dryers with HEPA Filtration Systems remove 99.999 percent of viruses from the airstream, something paper will never be able to do.”
Conversely, paper towels may not be as hygienic as the public believes. One independent study showed 17 species of bacteria on unused, recycled paper towels , including Bacillus, which can cause food poisoning. After their use, damp paper towels are a breeding ground for viruses and bacteria in and around trash receptacles and can be used to clog toilets and sinks creating a very unhygienic restroom environment. If the paper towels are out of stock, visitors cannot dry their hands at all, and wet hands have been shown to be 1,000 times more likely to transfer germs than dry hands .
Gagnon concluded, “I encourage members of the public and those individuals charged with the creation of guidelines, reopening plans or facilities operations, to dive deeper into news articles and hygiene studies rather than simply believing sensationalized, click-bait headlines born from biased results. Hand dryers are safe and hygienic. They dry hands completely, and are a top defense against the spread of germs.”
About Excel Dryer, Inc.
Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630006010/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
